ASH Annual Meeting

CME ad

2023 ASH Annual Meeting

ODA-2023 ASH-Urvi Shah, MD-Podcast Interview_960x800
Amer Zeidan discusses the abstract he presented at ASH investigating hypomethylating agents for myelodysplastic syndromes.
At ASH 2023, Dr. Andrew Hantel discusses his study on oncologists' perspectives on ethical implications of AI in cancer care.
Fabian Mueller discusses his study which investigated CD19-targeted CAR T cells for refractory systemic autoimmune diseases.
Dr. Andre Goy discusses his ASH 2023 abstract on expanded access for brexucabtagene autoleucel for mantle cell lymphoma.
Dr. Alex Boucher shares his research on racial disparities in stigmatizing language in the electronic medical record.
1 2

2022 ASH Annual Meeting

Habte Yimer discusses the ASH 2022 results of brentuximab vedotin for advanced-stage classical Hodgkin lymphoma.
Dr. Ira Zackon discusses his ASH presentation on real-world treatment and outcomes for myelodysplastic syndromes.
Armin Ghobadi discusses his research in the ZUMA-7 trial and the outcomes of patients with diffuse large B-cell lymphoma.
Ola Oluwole discusses his ASH abstracts on prophylactic corticosteroids and cytokine release syndrome with CAR T-cell therapy.
b2ap3_large_ASH-2022-Podcast-Mitul-Gandhi-MD_960x800-compressed
Dr. Hun Lee discusses his ASH abstracts on zilovertamab for MCL, MZL, and CLL, and brentuximab for Hodgkin lymphoma.
Dr. Leon Bernal-Mizrachi sits down to discuss his research and presentation regarding socioeconomic disparities in myeloma.
Dr. Ariela Marshall highlights the ASH Women in Hematology Working Group, dedicated to career development and leadership.
Dr. Shakira Grants discusses her ASH abstract about factors leading to Black patient disparities in hematology trials.
Dr. Ian Bouligny discusses health care disparities in AML and strategies for equalizing health care accessibility.
Dr. Robert Rifkin discusses COVID-19 impact on multiple myeloma treatment patterns and sequencing, as presented at ASH.
Dr. Noopur Raje discusses the results of the MagnetisMM-1 study of elranatamab for multiple myeloma that she presented.
Dr. Samer Al Hadidi discusses CAR T wait times and high-risk myeloma disease definitions at the 2022 ASH Annual Meeting.
Dr. Ajai Chari discusses results of the MonumenTAL study of talquetamab for multiple myeloma, presented at ASH 2022.
Dr. Luke Walker discusses the results of HPN217 in relapsed/refractory multiple myeloma that were presented at ASH 2022.
1 2
CME ad